Dr. Jain on Treatment Options for Patients With Myelofibrosis Who Progress After Transplant

Video

In Partnership With:

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Tania Jain, MBBS, assistant professor of oncology, Division of Hematological Malignancies and Stem Cell Transplantation, Johns Hopkins University, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant (allo-SCT).

Selecting a treatment for patients who progress following allo-SCT largely depends on what kind of relapse occurs, explains Jain.

For example, patients who have a molecular relapse in which a JAK mutation or other molecular driver is positive should be considered for a donor lymphocyte infusion (DLI). Though, DLI is associated with an increased risk of graft-versus-host disease, says Jain.

Additionally, all patients who relapse after allo-SCT can receive JAK inhibition to reduce symptoms or splenomegaly.

Patients whose myelofibrosis transforms to acute myeloid leukemia (AML) should receive therapies that are indicated for patients with AML, says Jain.

In rare circumstances, younger patients may be considered for a second allo-SCT, concludes Jain.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute